Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Debt: 2019-2024

Historic Non-Current Debt for Akebia Therapeutics (AKBA) over the last 5 years, with Dec 2024 value amounting to $38.7 million.

  • Akebia Therapeutics' Non-Current Debt rose 24.21% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 24.21%. This contributed to the annual value of $38.7 million for FY2024, which is 125.18% up from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Non-Current Debt is $38.7 million, which was up 125.18% from $17.2 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Non-Current Debt high stood at $96.4 million for FY2020, and its period low was $17.2 million during FY2023.
  • Over the past 3 years, Akebia Therapeutics' median Non-Current Debt value was $34.1 million (recorded in 2022), while the average stood at $30.0 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first slumped by 49.58% in 2023, then skyrocketed by 125.18% in 2024.
  • Yearly analysis of 4 years shows Akebia Therapeutics' Non-Current Debt stood at $96.4 million in 2020, then reached $34.1 million in 2022, then slumped by 49.58% to $17.2 million in 2023, then skyrocketed by 125.18% to $38.7 million in 2024.